United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

2 Dec 2016
Change (% chg)

€0.37 (+0.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Monsanto sets special shareholder meeting date to vote on merger proposal with Bayer
Tuesday, 1 Nov 2016 08:00am EDT 

Monsanto Company :Monsanto co - designated December 13, 2016 as date for a special meeting of shareowners to vote upon proposal to adopt merger agreement with Bayer.  Full Article

FDA concludes Xarelto clinical trial results not affected by Alere's INRatio
Tuesday, 11 Oct 2016 12:41pm EDT 

U.S. FDA: Analyses conclude that Xarelto clinical trial results were not affected by Alere's faulty monitoring device INRatio .FDA concludes blood thinner drug Xarelto is a safe and effective alternative to warfarin in patients with atrial fibrillation.  Full Article

Monsanto Q4 Loss Per Share of $0.44 on an as-reported basis
Wednesday, 5 Oct 2016 09:10am EDT 

Monsanto Co : Continued Soybean Technology Expansion And Cost Discipline Expected To Drive Return To EPS Growth In FY17 . Initial Steps Underway To Close On Deal With Bayer To Unlock Value For Shareowners . Continued Soybean Technology Expansion And Cost Discipline Expected To Drive Return To Eps Growth In Fy17 . Q4 Earnings Per Share View $-0.03, Revenue View $2.36 Billion -- Thomson Reuters I/B/E/S . Company Reiterated Confidence In Timelines To Close Deal With Bayer By End Of Calendar Year 2017 . In 2017, Company Expects Agricultural Productivity Segment To Deliver $900 Million To $1 Billion Of Gross Profit . In Soybeans, Greater Than 20 Percent Growth In Gross Profit, Coupled With Margin Improvement, Is Expected Year-Over-Year In Fiscal 2017 . Operating Expenses In 2017 Expected To More Than Offset Savings From Restructuring And Cost-Savings Plans . Sees FY 2017 Earnings Per Share $3.83 To $4.35 . Sees As-Reported FY17 EPS Guidance At $3.83 To $4.35 And Ongoing EPS Guidance At $4.50 To $4.90 . Qtrly Net Sales $2,562 Million Versus $2,355 Million Last Year . For Q4, Company Reported $0.44 Loss Per Share On An As-Reported Basis . For Q4, Company Reported $0.07 Earnings Per Share On An Ongoing Basis . Qtrly Ongoing EPS Results Were Better Than Fiscal Year 2015, Driven By $157 Million Gain From Formation Of Sorghum Joint Venture With Remington . FY2017 Earnings Per Share View $4.91, Revenue View $13.83 Billion -- Thomson Reuters I/B/E/S.  Full Article

Bayer receives EU approval for new five-year contraceptive
Tuesday, 4 Oct 2016 04:06am EDT 

Bayer AG : Receives green light for new five-year contraceptive in EU Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Bayer and DelSiTech partner to develop drug delivery technology for Ophthalmology
Thursday, 29 Sep 2016 02:30am EDT 

Bayer Ag : Delsitech to receive number of undisclosed milestone payments triggered by successful completion of different stages of development . Bayer and delsitech partner to develop drug delivery technology for ophthalmology .Bayer will fund all development and commercialization costs of collaborative projects.  Full Article

Bayer To start phase III study with Vericiguat
Wednesday, 28 Sep 2016 02:35am EDT 

Bayer AG : Says first patient was enrolled in Victoria, a pivotal phase III clinical study led by Bayer's collaboration partner msd . Says development and commercialization of Vericiguat is part of worldwide strategic collaboration between bayer and msd . Says victoria will enroll approximately 4,900 patients at 530 centres in 39 countries and it is anticipated that study will take 39 months to complet . Says received phase iii approval for vericiguat study . Says event-driven phase iii victoria study will assess efficacy and safety of vericiguat up to 10 mg once daily compared to placebo Further company coverage: [BAYGn.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Monsanto India says board to consider Bayer's open offer on Sept 26
Thursday, 22 Sep 2016 05:30am EDT 

Monsanto India Ltd : Meeting on Sept 26 to consider announcement made by Bayer on September 19 regarding open offer Further company coverage: [MNSN.NS] ((ReutersIndia.snapping@thomsonreuters.com;)).  Full Article

Evotec, Bayer to develop new treatments to fight kidney diseases
Wednesday, 21 Sep 2016 01:29am EDT 

Evotec AG : Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients . Says partners will share responsibilities during pre-clinical development of potential clinical candidates . Says will receive a minimum of eur 14 m over contract period including research payments and an undisclosed licence fee . Says is eligible to receive pre-clinical, clinical and sales milestones of potentially over eur 300 m as well as tiered royalties of up to low double-digit percentage of net sales .Says evotec and bayer partner to develop new treatments to fight kidney diseases.  Full Article

Bayer & Monsanto seen closing in on deal - CNBC, citing sources
Tuesday, 6 Sep 2016 09:00am EDT 

: Bayer & Monsanto seen closing in on deal; Monsanto told Bayer it is "close" on price- CNBC, citing sources . Bayer, Monsanto deal could happen within a week or two- CNBC, Citing Sources.  Full Article

Monsanto confirms updated proposal from Bayer
Monday, 5 Sep 2016 10:53pm EDT 

: Monsanto confirms updated proposal from Bayer . Monsanto Company - Confirmed it has been engaged in constructive negotiations with Bayer AG . Monsanto Company - Has received an updated non-binding proposal for a potential acquisition of Monsanto for $127.50 per share in cash. .Monsanto Company - Continuing conversations as it evaluates Bayer's proposal, as well as proposals from other parties and other strategic alternatives.  Full Article

BRIEF-Monsanto provides update on Bayer merger

* Monsanto co - in connection with merger with Bayer, a purported class action lawsuit, captioned ken gawrych, was filed on nov. 16, 2016